Molecularly, it was shown that EZH2 silences Wnt antagonists, such as DKK1 and AXIN2, leading to Wnt/β-catenin signaling activation in hepatocellular carcinoma [73]. The gene discussed is AXIN2; the disease is hepatocellular carcinoma.